INSPInspire Medical Systems, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for a decline (~−3% a year). The price demands less than its three-year revenue growth of 20% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What INSP's price assumes
Inspire Medical Systems, Inc. trades at 15.2× earnings against 26.2× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 26.2 · cheaper than the typical name in its group
- Price / sales
- 1.37
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 9.3%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- −2.7%
Growth the price implies · The price pays for −2.7% free cash flow growth a year for a decade; the business has delivered +84% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 1.60
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 18.5
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 1.03
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Free cash flow, trailing twelve months
- $117M
- Market capitalisation
- $1.25B
- 3-year revenue growth
- +20%
- 3-year free cash flow growth
- +84%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.